395 related articles for article (PubMed ID: 24606520)
1. Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARα) and its lipid ligands.
Fidaleo M; Fanelli F; Ceru MP; Moreno S
Curr Med Chem; 2014; 21(24):2803-21. PubMed ID: 24606520
[TBL] [Abstract][Full Text] [Related]
2. Palmitoylethanolamide in CNS health and disease.
Mattace Raso G; Russo R; Calignano A; Meli R
Pharmacol Res; 2014 Aug; 86():32-41. PubMed ID: 24844438
[TBL] [Abstract][Full Text] [Related]
3. Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia.
Holubiec MI; Romero JI; Suárez J; Portavella M; Fernández-Espejo E; Blanco E; Galeano P; de Fonseca FR
Psychopharmacology (Berl); 2018 Oct; 235(10):2929-2945. PubMed ID: 30058012
[TBL] [Abstract][Full Text] [Related]
4. Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α.
Scuderi C; Valenza M; Stecca C; Esposito G; Carratù MR; Steardo L
J Neuroinflammation; 2012 Mar; 9():49. PubMed ID: 22405189
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease.
Esposito E; Impellizzeri D; Mazzon E; Paterniti I; Cuzzocrea S
PLoS One; 2012; 7(8):e41880. PubMed ID: 22912680
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism.
Sun Y; Alexander SP; Garle MJ; Gibson CL; Hewitt K; Murphy SP; Kendall DA; Bennett AJ
Br J Pharmacol; 2007 Nov; 152(5):734-43. PubMed ID: 17906680
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.
Aleshin S; Strokin M; Sergeeva M; Reiser G
Neurochem Int; 2013 Oct; 63(4):322-30. PubMed ID: 23811400
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors and the control of inflammation.
Cabrero A; Laguna JC; Vázquez M
Curr Drug Targets Inflamm Allergy; 2002 Sep; 1(3):243-8. PubMed ID: 14561188
[TBL] [Abstract][Full Text] [Related]
9. Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α.
Koch M; Kreutz S; Böttger C; Benz A; Maronde E; Ghadban C; Korf HW; Dehghani F
Neurotox Res; 2011 Feb; 19(2):330-40. PubMed ID: 20221904
[TBL] [Abstract][Full Text] [Related]
10. Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease.
Scuderi C; Steardo L
CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):62-9. PubMed ID: 23394526
[TBL] [Abstract][Full Text] [Related]
11. Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation.
Esposito G; Capoccia E; Turco F; Palumbo I; Lu J; Steardo A; Cuomo R; Sarnelli G; Steardo L
Gut; 2014 Aug; 63(8):1300-12. PubMed ID: 24082036
[TBL] [Abstract][Full Text] [Related]
12. Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPARα.
Karwad MA; Macpherson T; Wang B; Theophilidou E; Sarmad S; Barrett DA; Larvin M; Wright KL; Lund JN; O'Sullivan SE
FASEB J; 2017 Feb; 31(2):469-481. PubMed ID: 27623929
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-α, on the management and prevention of obesity.
Tutunchi H; Saghafi-Asl M; Ostadrahimi A
Clin Exp Pharmacol Physiol; 2020 Apr; 47(4):543-552. PubMed ID: 31868943
[TBL] [Abstract][Full Text] [Related]
14. Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence.
Colizzi M; Bortoletto R; Costa R; Zoccante L
Nutrients; 2021 Apr; 13(4):. PubMed ID: 33919499
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptors and inflammation.
Moraes LA; Piqueras L; Bishop-Bailey D
Pharmacol Ther; 2006 Jun; 110(3):371-85. PubMed ID: 16168490
[TBL] [Abstract][Full Text] [Related]
16.
Li M; Wang D; Bi W; Jiang ZE; Piao R; Yu H
J Pharmacol Exp Ther; 2019 Apr; 369(1):163-172. PubMed ID: 30635472
[No Abstract] [Full Text] [Related]
17. In vivo brain levels of acetylcholine and 5-hydroxytryptamine after oleoylethanolamide or palmitoylethanolamide administrations are mediated by PPARα engagement.
Murillo-Rodríguez E; Arankowsky-Sandoval G; Budde H; Imperatori C; Machado S; Yamamoto T; Yadollahpour A; Torterolo P
Eur J Neurosci; 2021 Sep; 54(6):5932-5950. PubMed ID: 34396611
[TBL] [Abstract][Full Text] [Related]
18. Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells.
Camoglio C; Balla J; Fadda P; Dedoni S
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611871
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons.
Khasabova IA; Xiong Y; Coicou LG; Piomelli D; Seybold V
J Neurosci; 2012 Sep; 32(37):12735-43. PubMed ID: 22972997
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptors: from genes to physiology.
Kliewer SA; Xu HE; Lambert MH; Willson TM
Recent Prog Horm Res; 2001; 56():239-63. PubMed ID: 11237216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
